CLINICAL TRIALS PROFILE FOR HYDELTRASOL

All Clinical Trials for Hydeltrasol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00900445 ↗	Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia	Withdrawn	National Cancer Institute (NCI)		2008-03-24	This clinical trial is studying body mass index in younger patients receiving prednisone/prednisolone, vincristine, daunorubicin, and pegaspargase for high-risk acute lymphoblastic leukemia. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the affect of body mass index on the way anticancer drugs work in the body. It may also help doctors predict how patients will respond to treatment
NCT00900445 ↗	Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia	Withdrawn	Children's Oncology Group		2008-03-24	This clinical trial is studying body mass index in younger patients receiving prednisone/prednisolone, vincristine, daunorubicin, and pegaspargase for high-risk acute lymphoblastic leukemia. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the affect of body mass index on the way anticancer drugs work in the body. It may also help doctors predict how patients will respond to treatment
NCT02828358 ↗	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	2017-03-27	This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement. Drugs used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride, cytarabine, dexamethasone, vincristine sulfate, pegaspargase, hydrocortisone sodium succinate, azacitidine, cyclophosphamide, mercaptopurine, leucovorin calcium, and thioguanine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug may kill more cancer cells.

Clinical Trial Conditions for Hydeltrasol

Condition Name

Condition Name for Hydeltrasol
Intervention	Trials
B Acute Lymphoblastic Leukemia	5
Mixed Phenotype Acute Leukemia	3
Acute Lymphoblastic Leukemia	2

Condition MeSH

Condition MeSH for Hydeltrasol
Intervention	Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma	8
Leukemia, Lymphoid	8
Leukemia	8

Clinical Trial Locations for Hydeltrasol

Trials by Country

Trials by Country for Hydeltrasol
Location	Trials
United States	233
Canada	30
Australia	15
New Zealand	6
Puerto Rico	4

Trials by US State

Trials by US State for Hydeltrasol
Location	Trials
Texas	6
Tennessee	6
South Carolina	6
Pennsylvania	6
Oklahoma	6

Clinical Trial Progress for Hydeltrasol

Clinical Trial Phase

Clinical Trial Phase for Hydeltrasol
Clinical Trial Phase	Trials
Phase 3	6
Phase 2	2
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for Hydeltrasol
Clinical Trial Phase	Trials
Not yet recruiting	4
Recruiting	4
Withdrawn	1

Clinical Trial Sponsors for Hydeltrasol

Sponsor Name

Sponsor Name for Hydeltrasol
Sponsor	Trials
National Cancer Institute (NCI)	9
Children's Oncology Group	5
EsPhALL network I-BFM Study Group	1

Sponsor Type

Sponsor Type for Hydeltrasol
Sponsor	Trials
NIH	9
Other	6

Clinical Trials, Market Analysis, and Projections for Hydeltrasol (Prednisolone)

Introduction

Hydeltrasol, a brand name for the glucocorticoid prednisolone, is widely used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. This article provides an update on clinical trials involving prednisolone, a market analysis, and projections for its use.

Clinical Trials Involving Prednisolone

While there are no specific clinical trials listed under the name "Hydeltrasol," numerous studies involve prednisolone due to its broad therapeutic applications.

Current and Recent Trials

• Combination Therapies: Prednisolone is often used in combination with other treatments in various clinical trials. For example, in trials for breast cancer, prednisolone might be used to manage side effects or as part of a combination therapy to enhance the efficacy of other drugs[1].
• Autoimmune and Inflammatory Conditions: Prednisolone is frequently used in trials for autoimmune and inflammatory diseases. For instance, it may be part of treatment protocols for conditions like rheumatoid arthritis or allergic reactions[5].

Ongoing Research

• Cancer Treatment: In some cancer trials, prednisolone is used to mitigate the side effects of chemotherapy or as an adjunct therapy to improve patient outcomes. For example, in the context of breast cancer, it might be used in combination with endocrine therapies or other anticancer agents[1].
• Rare Diseases: Prednisolone may also be used in clinical trials for rare diseases, such as Dravet syndrome, where it could be part of a treatment regimen to manage symptoms or as a control group comparator[4].

Market Analysis

Global Clinical Trials Market

The global clinical trials market is projected to grow significantly, driven by the increasing prevalence of chronic diseases. This growth is expected to reach $106.78 billion by 2032, with a Compound Annual Growth Rate (CAGR) of 7.1% from 2024 to 2032[3].

Prednisolone Market

Prednisolone, being a widely used glucocorticoid, benefits from this overall growth in clinical trials. Its versatility in treating various conditions ensures a steady demand.

• Usage in Different Therapeutic Areas: Prednisolone is indicated for a wide range of conditions, including endocrine, rheumatic, hematologic, and dermatologic diseases. This broad applicability contributes to its consistent market presence[5].

Market Projections

Growth Drivers

• Increasing Prevalence of Chronic Diseases: The rising incidence of chronic diseases globally is a significant driver for the growth of the clinical trials market, which in turn benefits drugs like prednisolone[3].
• Advancements in Healthcare: Improvements in healthcare infrastructure and the increasing adoption of advanced therapeutic options are expected to boost the demand for prednisolone in various clinical settings.

Market Trends

• Cost-Effectiveness: Prednisolone is a cost-effective treatment option, which makes it a preferred choice in many clinical settings, especially in regions with limited healthcare resources.
• Combination Therapies: The trend towards combination therapies, where prednisolone is often used alongside other medications, is expected to continue, driving its market growth.

Key Takeaways

• Clinical Trials: Prednisolone is involved in numerous clinical trials across various therapeutic areas, including cancer, autoimmune diseases, and rare conditions.
• Market Growth: The global clinical trials market is expected to grow significantly, with prednisolone benefiting from this trend due to its broad therapeutic applications.
• Market Projections: The demand for prednisolone is projected to remain strong, driven by the increasing prevalence of chronic diseases and advancements in healthcare.

FAQs

What is Hydeltrasol?

Hydeltrasol is a brand name for the glucocorticoid prednisolone, used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

What conditions is prednisolone used to treat?

Prednisolone is indicated for a wide range of conditions, including endocrine, rheumatic, hematologic, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases, as well as allergic and edematous states[5].

Is prednisolone used in clinical trials for cancer?

Yes, prednisolone is often used in clinical trials for cancer, either as part of combination therapies or to manage side effects of other treatments[1].

What is the projected growth of the global clinical trials market?

The global clinical trials market is projected to grow from $61.58 billion in 2024 to $106.78 billion by 2032, at a CAGR of 7.1%[3].

Why is prednisolone a preferred treatment option?

Prednisolone is a preferred treatment option due to its cost-effectiveness, broad therapeutic applications, and established safety profile[5].

Sources

1. UCSF Breast Cancer Clinical Trials - UCSF Health
2. FDA Document: Delstrigo - FDA
3. Clinical Trials Market SIZE, SHARE | GROWTH REPORT [2032] - Fortune Business Insights
4. Current Research Studies & Pipeline - Dravet Syndrome Foundation
5. Prednisolone: Uses, Interactions, Mechanism of Action - DrugBank